NIIMBL Funds Projects with $10 Million for Advances in Biopharma Manufacturing Innovation

May 20, 2020

This latest round of funding adds 14 new technology projects, workforce development, and Global Health Fund projects to NIIMBL's portfolio.

mRNA Vaccine Shows Positive Interim Phase I Results

May 19, 2020

Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.

Catalent, Arcturus Therapeutics Sign Vaccine Deal

May 05, 2020

Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.

Commentary: A Competitive Marketplace for Biosimilars

May 05, 2020

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

Remdesivir Approved for Emergency Use

May 02, 2020

FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.

How Fast Is Too Fast?

May 01, 2020

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

Good Automation Practices for Remote Operations

May 01, 2020

Having remote operations in place is crucial to maintaining good automation practices.

Gene Therapies Push Viral Vector Production

May 01, 2020

Viral vectors show promise as a delivery mechanism for gene therapy, but which virus types are commercially viable?

Biomanufacturing: Demand for Continuous Bioprocessing Increasing

May 01, 2020

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

Studies Report Effectiveness of Remdesivir

April 29, 2020

NIH trial shows remdesivir accelerates recovery; Gilead study shows similar efficacy for 5- and 10-day dosing.